Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa clinical trial of resveratrol (JNS-115) in patients with Parkinson's Disease

Next Previous
Trial Profile

A Phase IIa clinical trial of resveratrol (JNS-115) in patients with Parkinson's Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resveratrol (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Nov 2025 According to Jupiter Neurosciences media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL in patients with Parkinson's disease. Trial initiation expected in early 2026.
  • 27 Oct 2025 According to Jupiter Neurosciences media release, company enters into agreements for up to $20 million in flexible financing. company intends to use the proceeds from these facilities primarily to support the Phase 2 trial of its lead asset to complete.
  • 08 Apr 2025 According to Jupiter Neurosciences, this trial is on track to begin dosing in Q3 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top